VisionGate Inc is a BioTech firm organized around brig to use-condition as cancer diagnostics platform based on the companyâs patented technology: Optical Projection Tomography (OPT). The platform, Cell-CT, is a non-invasive test for the early detection of lung cancer that generates high-resolution 3D biosignatures from cells in a sputum sample. VisionGateâs first commercial product, LuCED®, focuses on the #1 cancer killer â lung cancer. LuCED is a non-invasive test to aid physicians in the early detection of lung cancer utilizing sputum (phlegm). LuCED creates automated 3D images of cells in sputum, essentially taking a CT scan of individual cells. Once a 3D image is created, a smart computer program (algorithm) determines normal from abnormal cells, allowing for earlier disease detection. Although the CT scan has been around since 1970, this is the first time an individual cell has been able to be viewed in 3D â a capability of LuCED with more than 100 patents surrounding its deve
